22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
22:22 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
22:57 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Brain cancer; colorectal cancer; viral infection Mouse studies suggest inhibiting HPK1 kinase activity alone or in combination with PD-L1 inhibitors could help treat brain cancer, colorectal cancer and lymphocytic choriomeningitis virus (LCMV) infection. In...
23:08 , Oct 3, 2018 |  BC Extra  |  Preclinical News

Kinase identified as new cancer immunotherapy target

Genentech Inc. scientists identified a kinase as a new cancer immunotherapy target in a Cell Reports study led by VP of Cancer Immunology Ira Mellman. The results suggest that inactivation of the kinase enhances T...